Key result
Novel scaffold APC improves in vitro antiviral activity against SARS-CoV-2 delta variant with EC50 ~8 μM.
Why the study?
Viral ion channels have low mutation rates and are emerging targets for antiviral drugs to address resistance, but effective molecular scaffolds need redesigning.
Redesigning the molecular scaffold of viral ion channel blockers yielded novel compounds like APC with improved in vitro antiviral activity and lower cytotoxicity against SARS-CoV-2 variants.
The rise of rapidly mutating viruses poses growing challenges for drug developers in the fight against antiviral resistance. Viral ion channels generally have low mutation rates and are therefore considered emerging targets for a sustainable solution to the problem of resistance. This study reports the redesign of scaffolds for drug candidates targeting viral ion channels. The redesign was powered by a combination of a computational docking protocol that accounts for water molecules (HydroDock) and a subsequent quantum mechanics-based scoring (QMH-L) of the drug candidates. Extending the antiviral amantadine led to new compounds that better match the alternating hydrophobic and hydrophilic patterns of the inner walls of ion channels-a common feature across many viruses. Simplifying the structure yielded a cyclohexylamine-based minimalist scaffold that demonstrates improved antiviral activity compared to other agents such as amantadine and arterolane. SARS-CoV-2 variants served as test systems in laboratory experiments. The new molecular scaffolds presented here provide a strong foundation for designing potent viral ion channel blockers, helping to fill the drug pipeline.
No takes yet. Share an insight, caveat, or question.
Zsidó et al. (2026) studied SARS-CoV-2 infection (in vitro). Redesigned viral ion channel blockers (e.g., APC, PAC, ETA) vs. FDA-approved AMS drugs (amantadine, arterolane) and untreated controls was evaluated on Antiviral activity (EC50) and cytotoxicity (CC50). The redesigned cyclohexylamine-based scaffold APC demonstrated improved in vitro antiviral activity against the SARS-CoV-2 delta variant (EC50 8.32 μM) compared to existing agents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: